Showing results (271-280 of 286) with videos related to
Sort By:
Pageof 29
The New England Journal of Medicine|September 22, 2021
Overall Survival Benefit with Tebentafusp in Metastatic Uveal MelanomaPaul Nathan, Jessica C Hassel, Piotr Rutkowski, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 8, 2014
Combined BRAF (Dabrafenib) and MEK inhibition (Trametinib) in patients with BRAFV600-mutant melanoma experiencing progression with single-agent BRAF inhibitorDouglas B Johnson, Keith T Flaherty, Jeffrey S Weber, et al.The New England Journal of Medicine|June 5, 2012
Safety and activity of anti-PD-L1 antibody in patients with advanced cancerJulie R Brahmer, Scott S Tykodi, Laura Q M Chow, et al.The New England Journal of Medicine|October 23, 2023
Three-Year Overall Survival with Tebentafusp in Metastatic Uveal MelanomaJessica C Hassel, Sophie Piperno-Neumann, Piotr Rutkowski, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 20, 2024
Phase I Study of Fianlimab, a Human Lymphocyte Activation Gene-3 (LAG-3) Monoclonal Antibody, in Combination With Cemiplimab in Advanced MelanomaOmid Hamid, Karl D Lewis, Amy Weise, et al.Cancer Discovery|April 8, 2024
Randomized Placebo-Controlled, Biomarker-Stratified Phase Ib Microbiome Modulation in Melanoma: Impact of Antibiotic Preconditioning on Microbiome and ImmunityIsabella C Glitza, Yongwoo David Seo, Christine N Spencer, et al.Cancer Research|November 11, 2021
Longitudinal SARS-CoV-2 mRNA Vaccine-Induced Humoral Immune Responses in Patients with CancerJane C Figueiredo, Noah M Merin, Omid Hamid, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 18, 2014
Adoptive transfer of MART-1 T-cell receptor transgenic lymphocytes and dendritic cell vaccination in patients with metastatic melanomaThinle Chodon, Begoña Comin-Anduix, Bartosz Chmielowski, et al.The Lancet. Oncology|June 28, 2015
Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trialAntoni Ribas, Igor Puzanov, Reinhard Dummer, et al.Cancer Immunology Research|April 16, 2017
Liver Metastasis and Treatment Outcome with Anti-PD-1 Monoclonal Antibody in Patients with Melanoma and NSCLCPaul C Tumeh, Matthew D Hellmann, Omid Hamid, et al.Pageof 29